1. United States Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
I

IN8bio, Inc.

INAB US

IN8bio, Inc.United States Composite

1.09

USD
-0.59
(-35.12%)
Capital Structure

•

in mil. unless spec.
Working Capital

•

in mil. unless spec.
Growth Rates

•

in mil. unless spec.
Quarterly Revenue

•

in mil. unless spec.
Quarterly Earnings Per Share

•

in mil. unless spec.
Quarterly Dividends Per Share

•

in mil. unless spec.
Business
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM and other cancers; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company develops INB-300 and INB-500 that are in preclinical phase for treatment of acute myeloid leukemia, and other solid and hematological tumor types. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is based in New York, New York.